Rouzier developed and validated a nomogram, which was based on oestrogen receptor status, clinical stage, histologic grade and number of pre‐operative chemotherapy cycles to predict distant metastasis‐free survival.20 Cheng et al developed a robust 4‐gene signature (SRPK1, PCCA, PRLR and FBP1) to predict distant relapse‐free survival (DRFS) for patients with HER2‐negative breast cancer following taxane and anthracycline‐based chemotherapy. The gene discussed is PCCA; the disease is breast carcinoma.